Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 14c

Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q3 EPS of ($0.63), $0.14 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $0 versus the consensus estimate of $88.89 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Invesco Mortgage Capital declares $0.12 monthly dividend for June 2026
• Venu Holding enters $250 million at-the-market stock offering agreement